A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 1 year and older
• All sexes
• No healthy volunteers
• Child, Adult, Older adult

Study population: Patient having presented disseminated borreliosis confirmed by molecular biology (Borrelia burgdorferi sl. or Borrelia miyamotoi) within 24 months of receiving treatment with an anti-CD20 monoclonal antibody between January 1, 2010, and July 30, 2025.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

About this study

Conditions

Borrelia Infections

Keywords

Borreliosis, Lyme, Borrelia Infections, Borrelia Burgdorferi, Borrelia Miyamotoi, Anti-CD20 monoclonal antibodies

Medical subject headings

Borrelia Infections, Lyme Disease

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Description of the clinical presentation of cases of disseminated borreliosis occurring in patients receiving anti-CD20 therapy in France

   The clinical presentation describes how the disease manifests in patients:

   • the symptoms,
   • their severity,
   • and their progression.

   Example:

   Two patients may have the same disease, but one will primarily experience fever while the other will have neurological symptoms. This is part of the clinical presentation.

   Measured: Up to 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted15 Jan 2026
2. Study start29 Aug 2025
3. Primary completionAug 2026 (estimated)
4. Study completion29 Aug 2026 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for Borrelia InfectionsStudies of the same condition, open and under way.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.